MXPA02012793A - Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion. - Google Patents
Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion.Info
- Publication number
- MXPA02012793A MXPA02012793A MXPA02012793A MXPA02012793A MXPA02012793A MX PA02012793 A MXPA02012793 A MX PA02012793A MX PA02012793 A MXPA02012793 A MX PA02012793A MX PA02012793 A MXPA02012793 A MX PA02012793A MX PA02012793 A MXPA02012793 A MX PA02012793A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- dosage forms
- controlled release
- therapeutic agents
- forms including
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000013270 controlled release Methods 0.000 title abstract 2
- 230000002496 gastric effect Effects 0.000 title abstract 2
- 230000014759 maintenance of location Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 229960001344 methylphenidate Drugs 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Manufacturing & Machinery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21383200P | 2000-06-23 | 2000-06-23 | |
| US21711000P | 2000-07-10 | 2000-07-10 | |
| US22321200P | 2000-08-04 | 2000-08-04 | |
| PCT/US2001/020134 WO2002000213A1 (en) | 2000-06-23 | 2001-06-22 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02012793A true MXPA02012793A (es) | 2004-07-30 |
Family
ID=27395915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02012793A MXPA02012793A (es) | 2000-06-23 | 2001-06-22 | Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1305021A4 (enExample) |
| JP (1) | JP2004501190A (enExample) |
| KR (1) | KR20030013460A (enExample) |
| AU (2) | AU2001268722B8 (enExample) |
| CA (1) | CA2412490A1 (enExample) |
| CZ (1) | CZ2003199A3 (enExample) |
| EA (1) | EA200300046A1 (enExample) |
| HU (1) | HUP0301465A3 (enExample) |
| IL (1) | IL153497A0 (enExample) |
| MX (1) | MXPA02012793A (enExample) |
| WO (1) | WO2002000213A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608640B2 (en) | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
| IL160363A0 (en) * | 2001-08-16 | 2004-07-25 | Oregon State | Expandable gastric retention device |
| BE1015608A6 (fr) | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
| US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| WO2004091601A1 (fr) * | 2003-04-17 | 2004-10-28 | Jallal Messadek | Formulations orales flottantes pour la liberation controlee de la betaine |
| CA2553156A1 (en) * | 2003-10-20 | 2005-05-12 | Teva Pharmaceutical Industries Ltd. | Composition and dosage form for sustained effect of levodopa |
| JP2005132803A (ja) * | 2003-10-31 | 2005-05-26 | Ono Pharmaceut Co Ltd | 胃内滞留固形剤 |
| TW200533391A (en) | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
| FR2874325B1 (fr) * | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
| WO2006050581A2 (en) | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
| EP2242489A1 (en) | 2005-02-15 | 2010-10-27 | Jallal Messadek | Combination therapeutic compositions and method of use |
| EP1885392B1 (en) | 2005-04-27 | 2012-01-11 | Jallal Messadek | Insulins combinations |
| NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| MX2008015339A (es) * | 2006-05-31 | 2008-12-16 | Solvay Pharm Gmbh | Administracion intestinal a largo plazo durante 24 horas de levodopa/carbidopa. |
| EP1872775A1 (en) | 2006-06-29 | 2008-01-02 | Polichem S.A. | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
| AR062659A1 (es) * | 2006-09-08 | 2008-11-26 | Drug Tech Corp | Composicion de liberacion sostenida de levodopa y metodo para su uso |
| WO2008039186A2 (en) * | 2006-09-26 | 2008-04-03 | Plensat, Llc | Method and system for treatment of eating disorders |
| CA2673485A1 (en) | 2007-01-15 | 2008-07-24 | Kissei Pharmaceutical Co., Ltd. | Gastric retention-type sustained-release levodopa preparation |
| KR20080076382A (ko) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
| DE102007026037A1 (de) * | 2007-06-04 | 2008-12-11 | Lts Lohmann Therapie-Systeme Ag | Gastroretentives System mit Alginat-Körper |
| US20090028941A1 (en) * | 2007-07-27 | 2009-01-29 | Depomed, Inc. | Pulsatile gastric retentive dosage forms |
| AU2009267052B2 (en) | 2008-06-30 | 2013-07-11 | Tocagen Inc. | Formulations of 5-fluorocytosine and uses thereof |
| AU2009281752B2 (en) * | 2008-08-15 | 2016-11-17 | Depomed Inc. | Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders |
| CN102238946B (zh) * | 2008-11-07 | 2014-11-26 | 株式会社三养生物制药 | 用于哌醋甲酯的控制释放的药物组合物 |
| WO2012093974A1 (en) * | 2011-01-06 | 2012-07-12 | Mahmut Bilgic | Improved bisphosphonate formulations |
| CN103385871B (zh) * | 2012-05-07 | 2017-06-23 | 新疆医科大学 | 复方左旋多巴微囊漂浮片 |
| US10507127B2 (en) | 2012-06-07 | 2019-12-17 | Epitomee Medical Ltd. | Expandable device |
| WO2014174388A1 (en) * | 2013-03-29 | 2014-10-30 | Wockhardt Limited | Modified release pharmaceutical compositions of methylphenidate or salts thereof |
| JP6204141B2 (ja) * | 2013-04-22 | 2017-09-27 | テイカ製薬株式会社 | 口腔内速崩壊性固形製剤用組成物 |
| WO2014176389A1 (en) * | 2013-04-24 | 2014-10-30 | Temple University - Of The Commonwealth System Of Higher Education | Solid dosage form containing arabinogalactan |
| JP6506271B2 (ja) | 2013-10-07 | 2019-04-24 | インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． | レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用 |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| AU2014358675B2 (en) * | 2013-12-05 | 2019-10-03 | Epitomee Medical Ltd | Retentive devices and systems for in-situ release of pharmaceutical active agents |
| MX2017011005A (es) * | 2015-02-27 | 2018-01-16 | Cingulate Therapeutics LLC | Formulaciones estimulantes de liberacion tripulsos. |
| JP6823539B2 (ja) * | 2017-05-26 | 2021-02-03 | 株式会社ファンケル | 胃内滞留性錠剤 |
| ES2928071T3 (es) | 2017-06-16 | 2022-11-15 | Amneal Complex Products Res Llc | Formas de dosificación gastrorretentiva para el suministro sostenido de fármacos |
| US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
| US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
| ES2861153T3 (es) | 2018-06-18 | 2021-10-05 | Composiciones de liberación prolongada que comprenden piridostigmina | |
| EP3628004B1 (en) | 2018-06-27 | 2021-09-22 | Amneal Complex Products Research LLC | Self-regulating osmotic gastroretentive drug delivery systems |
| JP7044649B2 (ja) * | 2018-06-28 | 2022-03-30 | 株式会社ファンケル | 胃内浮遊錠剤 |
| WO2020230089A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
| WO2020264092A1 (en) * | 2019-06-26 | 2020-12-30 | Celista Pharmaceuticals Llc | Atomoxetine hydrochloride extended release compositions and methods of use |
| WO2021176361A1 (en) * | 2020-03-02 | 2021-09-10 | Craft Health Pte Ltd | Method of manufacturing oral dosage forms for extended drug release |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| CA3196650A1 (en) | 2020-12-22 | 2022-06-30 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| US11571402B2 (en) * | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| BR9811478A (pt) * | 1997-07-23 | 2000-08-15 | Perio Prod Ltd | Composições de polìmero-ácido tânico para a liberação controlada de agentes farmacêuticos particularmente na cavidade oral |
-
2001
- 2001-06-22 JP JP2002504995A patent/JP2004501190A/ja active Pending
- 2001-06-22 AU AU2001268722A patent/AU2001268722B8/en not_active Ceased
- 2001-06-22 KR KR1020027017538A patent/KR20030013460A/ko not_active Ceased
- 2001-06-22 CA CA002412490A patent/CA2412490A1/en not_active Abandoned
- 2001-06-22 EA EA200300046A patent/EA200300046A1/ru unknown
- 2001-06-22 AU AU6872201A patent/AU6872201A/xx active Pending
- 2001-06-22 WO PCT/US2001/020134 patent/WO2002000213A1/en not_active Ceased
- 2001-06-22 HU HU0301465A patent/HUP0301465A3/hu unknown
- 2001-06-22 EP EP01946709A patent/EP1305021A4/en not_active Withdrawn
- 2001-06-22 CZ CZ2003199A patent/CZ2003199A3/cs unknown
- 2001-06-22 MX MXPA02012793A patent/MXPA02012793A/es not_active Application Discontinuation
- 2001-06-22 IL IL15349701A patent/IL153497A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1305021A4 (en) | 2009-09-23 |
| CA2412490A1 (en) | 2002-01-03 |
| EP1305021A1 (en) | 2003-05-02 |
| AU6872201A (en) | 2002-01-08 |
| AU2001268722B8 (en) | 2005-09-29 |
| HUP0301465A2 (hu) | 2004-05-28 |
| KR20030013460A (ko) | 2003-02-14 |
| AU2001268722B2 (en) | 2005-08-11 |
| HUP0301465A3 (en) | 2006-07-28 |
| WO2002000213A1 (en) | 2002-01-03 |
| EA200300046A1 (ru) | 2003-10-30 |
| CZ2003199A3 (cs) | 2003-12-17 |
| JP2004501190A (ja) | 2004-01-15 |
| IL153497A0 (en) | 2003-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02012793A (es) | Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion. | |
| MXPA02012792A (es) | Composicion y forma de de dosificacion para liberacion gastrica retardada de alendronato y/u otros bis-fosfonatos. | |
| NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
| DE602004032149D1 (de) | Oros-push-stick für die kontrollierte abgabe von wirkstoffen | |
| IS7006A (is) | Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd | |
| HUP0004300A2 (hu) | (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény | |
| AR027902A1 (es) | Preparacion medicamentosa plana para la administracion transmucosa de oxicodona o un principio activo similar en la cavidad bucal, para su aplicacion en el tratamiento contra el dolor y la adiccion | |
| DK0754034T3 (da) | Brusende farmaceutiske formuleringer indeholdende biologisk nedbrydelige mikrokapsler med kontrolleret afgivelse | |
| PT1471892E (pt) | Sistema terapêutico transdérmico para a doença de parkinson induzindo níveis elevados de rotigotina no plasma | |
| AU2357202A (en) | Ion-strength independent sustained release pharmaceutical formulation | |
| PL370529A1 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug | |
| GB2431346C (en) | A combination composition comprising paracetamol and ibuprofen | |
| MY137570A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease | |
| BR0108261A (pt) | Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono | |
| DE50000864D1 (de) | Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit | |
| HUP0301408A2 (hu) | Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására | |
| DE50010973D1 (de) | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus | |
| PT1572686E (pt) | Derivados de amida do ácido antranílico e suas utilizações farmacêuticas | |
| GEP20063804B (en) | Once-a-day oxycodone formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |